Immunoconjugates (Immunoconjugate)

Combinations of diagnostic or therapeutic substances linked with specific immune substances such as IMMUNOGLOBULINS; MONOCLONAL ANTIBODIES; or ANTIGENS. Often the diagnostic or therapeutic substance is a radionuclide. These conjugates are useful tools for specific targeting of DRUGS and RADIOISOTOPES in the CHEMOTHERAPY and RADIOIMMUNOTHERAPY of certain cancers.

Also Known As:

Networked: 3432 relevant articles (345 outcomes, 466 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Goldenberg, David M: 35 articles (01/2021 - 11/2003)
2.	Sharkey, Robert M: 26 articles (03/2020 - 11/2003)
3.	Zeglis, Brian M: 24 articles (03/2022 - 08/2013)
4.	Sapra, Puja: 24 articles (01/2022 - 07/2005)
5.	Senter, Peter D: 23 articles (01/2019 - 09/2005)
6.	Yu, Shang-Fan: 22 articles (03/2022 - 07/2007)
7.	Govindan, Serengulam V: 22 articles (03/2020 - 07/2005)
8.	Lewis, Jason S: 20 articles (03/2022 - 08/2013)
9.	Gerber, Hans-Peter: 20 articles (01/2022 - 07/2008)
10.	Reilly, Raymond M: 20 articles (01/2021 - 03/2006)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2018 - "Improved Total Synthesis of Tubulysins and Design, Synthesis, and Biological Evaluation of New Tubulysins with Highly Potent Cytotoxicities against Cancer Cells as Potential Payloads for Antibody-Drug Conjugates." 11/01/2016 - "RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models." 04/01/2016 - "The data suggest that deBouganin could be a highly effective against tumor cell phenotypes not being addressed by current antibody drug conjugate formats and thereby provide prolonged clinical benefit." 10/05/2015 - "Ultimately, this pretargeted PET imaging strategy boasts a dramatically improved pharmacokinetic profile compared to our first generation system and is capable of clearly delineating tumor tissue with high image contrast at only a fraction of the radiation dose created by directly labeled radioimmunoconjugates. " 01/01/2020 - "Antibody drug conjugates (ADCs), as potent pharmaceutical trojan horses for cancer treatment, provide superior efficacy and specific targeting along with low risk of adverse reactions compared to traditional chemotherapeutics. "
2.	Breast Neoplasms (Breast Cancer) 01/01/2023 - "Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. " 04/01/2020 - "Conclusions: The results indicated that the efficacy of both the radioimmunoconjugates, in terms of inducing cell death, was similar thereby ascertaining their potential as good therapeutic agents for patients with breast cancer." 08/24/2011 - "The aim of the present study was to explore the biodistribution, normal tissue toxicity, and therapeutic efficacy of the internalizing low-dose rate alpha-particle-emitting radioimmunoconjugate 227Th-trastuzumab in mice with HER2-expressing breast cancer xenografts. " 01/01/2023 - "HER3-targeting antibody-drug conjugates have demonstrated efficacy in HER3-expressing metastatic breast cancer and NSCLC. " 06/06/2023 - "Recently, antibody-drug conjugates have been found to have positive anticancer efficacy in patients with HER2-low breast cancer, but more studies are required to comprehend their clinical and molecular characteristics. "
3.	Ovarian Neoplasms (Ovarian Cancer) 11/15/2015 - "Preclinical Development of an Anti-NaPi2b (SLC34A2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian Cancers." 09/01/2021 - "CD70 antibody-drug conjugate: A potential novel therapeutic agent for ovarian cancer." 02/01/1994 - "The authors have been treating patients with ovarian cancer in Phase I and II studies assessing toxicity and response to improved radioimmunoconjugates. " 01/01/2020 - "Improved targeting of an anti-TAG-72 antibody drug conjugate for the treatment of ovarian cancer." 01/01/2023 - "Emerging data from phase 1 and 2 clinical trials in ovarian cancer have suggested that NaPi2b can be successfully detected in patient biopsy samples using immunohistochemistry, and the NaPi2b-targeting antibody-drug conjugate under evaluation appeared to elicit therapeutic responses. "
4.	Lymphoma (Lymphomas) 01/12/2023 - "Antibody drug conjugates represent a new class of novel targeted agents with significant improvement in therapeutic efficacy in the treatment of lymphomas. " 01/01/2018 - "A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas." 04/01/2020 - "New strategies for relapsed lymphomas are in development among which antibody-drug conjugates (ADCs) are currently in clinical trials. " 02/01/2011 - "Trial watch: antibody-drug conjugate shows efficacy in lymphoma." 12/15/1997 - "Lymphomas have been shown to be responsive to 131I immunoconjugates in studies conducted in mice and patients. "
5.	Carcinoma (Carcinomatosis) 10/01/2014 - "T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo." 11/01/2023 - "[Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma]." 01/01/2023 - "Antibody-Drug-Conjugates (ADC): A Novel Treatment Option in Urothelial Carcinoma." 01/01/1997 - "Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates." 01/01/2021 - "Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma."

Related Drugs and Biologics

1.	Monoclonal Antibodies
2.	trastuzumab deruxtecan
3.	Antibodies
4.	Ado-Trastuzumab Emtansine
5.	Brentuximab Vedotin
6.	Antigens
7.	Trastuzumab (Herceptin)
8.	human ERBB2 protein
9.	Chimeric Antigen Receptors
10.	Immunotoxins (Immunotoxin)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Radioimmunotherapy
5.	Adjuvant Chemotherapy